Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Fulcrum Therapeutics (FULC) over the last 6 years, with Q2 2025 value amounting to -$979000.0.

  • Fulcrum Therapeutics' Change in Receivables fell 14196.31% to -$979000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$3.7 million, marking a year-over-year decrease of 21885.57%. This contributed to the annual value of $1.6 million for FY2024, which is 40616.88% up from last year.
  • Fulcrum Therapeutics' Change in Receivables amounted to -$979000.0 in Q2 2025, which was down 14196.31% from -$1.1 million recorded in Q1 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Change in Receivables peaked at $2.6 million during Q4 2021, and registered a low of -$5.0 million during Q4 2022.
  • Over the past 5 years, Fulcrum Therapeutics' median Change in Receivables value was -$103000.0 (recorded in 2023), while the average stood at -$132687.5.
  • Over the last 5 years, Fulcrum Therapeutics' Change in Receivables had its largest YoY gain of 184078.95% in 2024, and its largest YoY loss of 352790.7% in 2024.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Change in Receivables stood at $2.6 million in 2021, then plummeted by 291.37% to -$5.0 million in 2022, then soared by 99.14% to -$43000.0 in 2023, then plummeted by 3527.91% to -$1.6 million in 2024, then soared by 37.24% to -$979000.0 in 2025.
  • Its Change in Receivables was -$979000.0 in Q2 2025, compared to -$1.1 million in Q1 2025 and -$1.6 million in Q4 2024.